All In Biotech

Drug Trial Radar · NCT04082520

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Apr 14, 2020

Primary completion

Sep 4, 2027

Study completion Mar 4, 2032

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered in the vein that is designed to target and kill tumor cells. The goal of this study is to determine whether this drug is safe and effective in treating meningiomas that progress after radiation treatment. WHO Grade I and Cohort WHO II/III cohorts will be evaluated.

Conditions

  • Grade 1 Meningioma
  • Grade 2 Meningioma
  • Grade 3 Meningioma
  • Recurrent Meningioma
  • Unresectable Meningioma

Interventions

  • Gallium Ga 68-DOTATATERadiation

    Given IV

  • Lutetium Lu 177 DotatateDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo PET/MRI

  • Positron Emission TomographyProcedure

    Undergo PET/MRI

  • Questionnaire AdministrationOther

    Ancillary studies

  • Computed TomographyProcedure

    Undergo PET/CT and/or SPECT/CT

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Single Photon Emission Computed TomographyProcedure

    Undergo SPECT/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival - 6 monthsTime frame: At 6 months after starting treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.